Release
2023/08/29
OSAKA, Japan, August 29, 2023 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that Flomox® Fine Granules for children (hereafter “this drug”) launched in China through our partner, Beijing Huawei Pharmaceutical Co. LTD (Head Office: Beijing, People’s Republic of China; Chairman: Guan Qingwei). This drug was listed on the National Reimbursement Drug List (NRDL) in January of this year.
In China, where sales have been launched this time, there are limited options for pediatric infectious disease treatment drugs, and this drug is expected to contribute as a new treatment option for pediatric infectious diseases.
Shionogi is committed to the principle “Protecting people worldwide from the threat of infectious diseases” as our key focus, and is working on the realization of total care for infectious diseases. Shionogi will continue to promote activities so that we can quickly deliver the anti-infective drugs necessary to protect people's health to patients around the world.
About Beijing Huawei Pharmaceutical Co. LTD
Beijing Huawei is a pharmaceutical company established in 1992, and has cooperated with many domestic companies in China and Japanese pharmaceutical companies, and has had good sales performance in the Chinese market. The main products sold include children, pain, immunity, anti-cancer drugs, anti-infective drugs, etc. Beijing Huawei has a sales network covering all major hospitals in China.
About The National Reimbursement Drug List (NRDL)
The NRDL is a list of drugs that are fully or partially reimbursed by public insurance for eligible patients, and is nationally approved with the aim of providing basic medical insurance to China's 1.4 billion people.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html